[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356497-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356497-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dysregulated-expression-of-cell-cycle-regulators-cdc20-plk1-bub1-cdc45-cdca5-in-pancreatic-ductal-adenocarcinoma","Dysregulated expression of cell cycle regulators CDC20, PLK1, BUB1, CDC45, CDCA5 in pancreatic ductal adenocarcinoma","","Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer with limited five-year survival and restricted molecular characterization in Pakistan. This study pools Pakistani PDAC RNA-seq data with seven NCBI-GEO datasets to identify shared hub genes across cohorts. CDC20, PLK1, BUB1, CDC45, and CDCA5 show concordant dysregulated expression, with upregulation in early PDAC stages. RT-qPCR confirms significant overexpression in Pakistani tumors, while whole exome sequencing highlights non-synonymous pathogenic variants in BUB1.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dysregulated-expression-of-cell-cycle-regulators-cdc20-plk1-bub1-cdc45-cdca5-in-pancreatic-ductal-adenocarcinoma/356497/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dysregulated-expression-of-cell-cycle-regulators-cdc20-plk1-bub1-cdc45-cdca5-in-pancreatic-ductal-adenocarcinoma/356497.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this PDAC study?","Question",{"text":63,"@type":64},"To identify hub genes involved in PDAC progression that could serve as diagnostic and therapeutic markers in Pakistani cohorts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which hub genes were highlighted across the pooled NCBI-GEO datasets?",{"text":68,"@type":64},"CDC20, PLK1, BUB1, CDC45, and CDCA5 were concordantly present across the seven NCI-GEO datasets together with the Pakistani RNA-seq dataset.",{"name":70,"@type":61,"acceptedAnswer":71},"How were the hub gene expression findings validated?",{"text":72,"@type":64},"RT-qPCR assessed expression in Pakistani PDAC tissue samples, and validation was complemented by whole exome sequencing (WES).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356497,1790564876,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDysregulated expression of cell cycle regulators CDC20, PLK1, BUB1, CDC45, CDCA5 in pancreatic ductal adenocarcinoma  \nMaryam Naeem1, Kainat Qadeer1, Ishrat Jabeen2, Ibrar Ahmed3,4, Iram Murtaza1, Javeria Farooq5 & Aneesa Sultan1􀀍  \nPancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with five years survival rate less than 5%. In Pakistan, transcriptomic profiling of pancreatic cancer is limited, with most evidence derived from in silico and isolated NGS analyses, highlighting the need for RNA-sequencing-based expression profiling in Pakistani PDAC cohorts. The purpose of this study is to report hub genes that are involved in progression of cancer and can be used as diagnostic and therapeutic markers. Pakistani PDAC RNAseq dataset was pooled with seven publicly available NCBI-GEO datasets (GSE136569, GSE119794, GSE164665, GSE119224, GSE211398, GSE196009, and GSE40174) to probe common hub genes. The expression of these hub genes in tumor samples was evaluated using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and validated through Whole Exome Sequencing. CDC20, PLK1, BUB1, CDC45, and CDCA5 were concordantly present in seven NCI-GEO Datasets along with Pakistani RNA-seq dataset. These hub genes were upregulated at the initial stages of PDAC.  \nRT-qPCR revealed significant upregulation in Pakistani tumor samples (*P \u003C 0.05, **P \u003C 0.001). WES analysis demonstrates non synonymous pathogenic variants in BUB1. The consistent dysregulated expression of the hub genes across independent NCBI-GEO datasets and the Pakistani RNA-seq cohort suggests their possible robustness across diverse populations and potential utility as broadly applicable biomarkers. These findings offer population-specific insights that may inform future biomarker-guided diagnostic and prognostic stratification of PDAC in Pakistan.  \nKeywords PDAC, In silico, RNA seq, Hub genes, Cell cycle, In vitro  \nPancreatic cancer is a very aggressive tumor with high metastatic propensity1. Despite its relatively lower incidence, pancreatic cancer is the 6th most common cause of cancer-related mortality worldwide, as reported by GLOBOCAN 20222. In Pakistan, the burden of pancreatic cancer is expected to increase four-fold by 20303. Despite this daunting situation, comprehensive molecular characterization of pancreatic ductal adenocarcinoma (PDAC) in Pakistan remains limited.  \nMost published studies from Pakistan have primarily focused on clinicopathological characteristics and epidemiological patterns of PDAC3. In addition, limited molecular investigations have been reported, including targeted DNA-sequencing studies describing alterations in key cancer-associated genes, such as KRAS, TP53, APC, and BRCA1 genes4. Furthermore, germline and somatic variant analyses of BRCA1/25 and CDKN2A6 have been explored in selected Pakistani PDAC cohorts. However, transcriptome-wide RNA-sequencing-based expression profiling of potential biomarkers in Pakistani cohorts remains limited and has largely been restricted to in silico analyses.  \nThe limited accuracy of current biomarkers for early detection of PDAC has necessitated intensified research into novel genomic and transcriptomic markers, particularly as the majority of PDAC cases are diagnosed at advanced, often unresectable stages7. To address this gap, RNA sequencing technology has become cardinal in cancer research especially in early diagnosis providing biological information on tumor cell, intratumoral  \n1Department of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan. 2Computational Drug Design Lab, School of Interdisciplinary Engineering & Sciences (SINES), National University of Sciences & Technology (NUST), Islamabad 44000, Pakistan. 3Alpha Genomics Private Limited, Islamabad 45710, Pakistan. 4Alpha Genomics Korea Co. Ltd., Daejeon 34386, Republic of Korea. 5National Centre for Bioinformatics, Quaid-i-A","cbCaivBvbjVyBPFY","https://ap.wps.com/l/cbCaivBvbjVyBPFY","pdf",3309865,"English","# Materials and methods\n## Sample collection and ethics approval","[{\"question\":\"What is the main objective of this PDAC study?\",\"answer\":\"To identify hub genes involved in PDAC progression that could serve as diagnostic and therapeutic markers in Pakistani cohorts.\"},{\"question\":\"Which hub genes were highlighted across the pooled NCBI-GEO datasets?\",\"answer\":\"CDC20, PLK1, BUB1, CDC45, and CDCA5 were concordantly present across the seven NCI-GEO datasets together with the Pakistani RNA-seq dataset.\"},{\"question\":\"How were the hub gene expression findings validated?\",\"answer\":\"RT-qPCR assessed expression in Pakistani PDAC tissue samples, and validation was complemented by whole exome sequencing (WES).\"}]","Dysregulated expression of cell cycle regulators CDC20, PLK1, BUB1, CDC45, CDCA5 in pancreatic ductal adenocarcinoma | PDF",1790125591,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30d19c6e31a3c687398d59ab30a66fc1.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a44ef45067529835f4225eaacc322d5.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ff29726140d442959cdb2599fc5b313.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09be810531fb83e0c53e6690f92a45a5.webp",980,1287]